阿拉格列汀

Anagliptin

未知生产厂商

Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

技术标识符

化学式: C₁₉H₂₅N₇O₂
CAS 编号: 739366-20-2
UNII ID: K726J96838

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

COMBINATION THERAPY FOR TREATING NEURODEGENERATIVE DISORDERS
EP 4808562 A1申请人: ARIBIO CO LTD优先权: 2023
CN
EP
WO
3 件公开
含有DPP-4抑制剂的用于预防或治疗瓣膜钙化的组合物
CN 107530446 B申请人: 财团法人峨山社会福祉财团优先权: 2015
CN
2 件公开
Crystal of n-[2-({2-[(2s)-2-cyanopyrrolidin-1-yl]-2- oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
CN 104520301 A申请人: SANWA KAGAKU KENKYUSHO CO优先权: 2013
CN
Preparation method of anagliptin
- CN 104974159 A
  申请人: CISEN PHARMACEUTICAL CO LTD优先权: 2014
  CN
- CN 115650984 A
  申请人: JIANGSU JUNRUO PHARMACEUTICAL CO LTD优先权: 2022
  CN
Preparation method of Anagliptin intermediate
CN 105315284 A申请人: SHANGHAI INST PHARM INDUSTRY优先权: 2014
CN
Synthesis method of anagliptin
CN 105503878 A申请人: HAIMEN BAIKANG PHARMACEUTICAL CO LTD优先权: 2014
CN
阿拉格列汀中间体的制备方法
CN 110003218 B申请人: 杭州瀚康生物医药科技有限公司优先权: 2019
CN
达格列净的固体形式复合物及其制备方法与应用
CN 114671839 B申请人: 天地恒一制药股份有限公司优先权: 2020
CN

药物

阿拉格列汀

概览

专利

Preparation method of anagliptin